ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ADCETRIS
Date registered
Evaluation commenced
Decision date
Approval time
185 working days (255)
Active ingredients
brentuximab vedotin
Registration type
EOI
Indication
ADCETRIS (powder for injection) is now also indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.